Solid Biosciences to Participate at Upcoming Investor Conferences
March 06, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
January 16, 2024 08:00 ET
|
Solid Biosciences Inc.
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision...
Solid Biosciences Announces $109 Million Private Placement
January 08, 2024 07:09 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
December 07, 2023 08:00 ET
|
Solid Biosciences Inc.
– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life...
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
November 22, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
November 14, 2023 16:05 ET
|
Solid Biosciences Inc.
– Planning to initiate Phase 1/2 trial in pediatric DMD Patients –– First cohort to study patients 4 to < 6 years of age –CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences...
Solid Biosciences to Participate at Jefferies London Healthcare Conference
November 09, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Provides Third Quarter Business Update and Financial Results
November 08, 2023 16:17 ET
|
Solid Biosciences Inc.
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter...